{
  "id": 1241560,
  "title": "Pennant group CEO Brent Guerisoli sells $165,066 in shares",
  "url": "https://urgent.news/2026/08/16/pennant-group-ceo-brent-guerisoli-sells-165-066-in-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-16T09:01:15.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/pennant-group-ceo-brent-guerisoli-sells-165066-in-shares-93CH-4861950"
  },
  "original_language": "en",
  "account": "On August 6, 2026, Brent Guerisoli, the CEO of Pennant Group Inc. (NASDAQ: PNTG), disposed of 4,285 shares of the company's common stock, selling them for a total of $165,066. The shares were sold at a price of $38.522 per share. Following this transaction, Mr. Guerisoli now owns 99,544 shares of Pennant Group common stock.\n\nWhile the stock has shown a robust 55.7% return over the past year and a nearly 40% increase year-to-date, InvestingPro analysis indicates that the shares may be overvalued relative to its estimated Fair Value. The company has been generating strong returns over the last year, as highlighted by 7 exclusive InvestingPro tips and a comprehensive Pro Research Report on its investment potential.\n\nThe sale of shares was conducted in accordance with a pre-approved Rule 10b5-1 trading plan, which was established on May 31, 2024. In a recent update, The Pennant Group reported impressive second-quarter 2026 financial results, surpassing Wall Street's expectations. The company reported adjusted earnings of $0.36 per share, exceeding the projected $0.33 per share. Revenue also exceeded estimates, totaling $298.0 million compared to the anticipated $288.66 million, representing a 35.8% year-over-year increase. Adjusted EBITDA showed a significant rise of 48.2%.\n\nFollowing these strong financial results, Wells Fargo adjusted its price target for The Pennant Group's stock from $45 to $46, maintaining an Overweight rating. This revised target reflects increased estimates for adjusted EBITDAR. These developments underscore the company's strong performance and growth potential, as recognized by Wells Fargo.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Pennant group chief clinical officer sells $53,699 in stock",
        "url": "https://urgent.news/2026/08/16/pennant-group-chief-clinical-officer-sells-53-699-in-stock",
        "published": "2026-08-16T09:01:13.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}